Yara, thanks for all you are working on.
Lots of us can't make it to Boston this weekend but would like to be part of the event.
Your ylb2 doesn't seem to allow direct emails
Thought you were talking about Mark Elliot.
You must be talking about Perrin. Whew!
In the eventuality that things work out as you describe, the top price per share will be whatever price Big Pharma buys NVIV.
Definitely not $32,000/share.
FWIW, I think your low estimates are a bit high in the number of patients. I also think your price for the procedure to reverse paralysis is too low (if this indeed occurs).
These statements always amuse me.
Parabolic with a positive or negative Y value? Both are possible.
They stone you when you try to make a buck.
They stone you then say good luck.
But I would not feel so all alone.
Everybody must get stoned.
Not sure how you calculate $19 million burn rate per year working out to about $1 millioin per month.
I also anticipate burn rate increasing as trials progress.
Punit and Avtar got tired of their employees Bogarting the joints.
Electroporation was found to increase the marijuana high.
Now the entire staff just sits around toking and shocking each other all day.
Invivo ended the year with $13 million. Issued shares in January raising another $12 million. Burn rate is a bit less than $2 million/month.
Between $20 and $22 million is now the cash on hand.
It seems the company likes to issue shares when they get down to roughly $10 million on hand. At current burn rate that would be about 6 months from now.
Yeah, but it would have been a lot nicer if he had given Jordan DIRT bike helmet instead of a ROAD bike helmet.
Are you SURE "we know EP/IL12 increases TIL's (density of CD8+ T cells)??
Where have you seen this?
EP/IL12 may increase TILs but I have yet to see evidence of CD8+ increase from IL 12. CD8+ is the TIL of interest for pembrolizumab.
My worry is that Oncosec is hoping for positive correlation rather than very confident of correlation.
Please post evidence of density of CD8+ increase due to IL12.